Bone Health: Protecting Your Bone Capital
Up to 20% of bone density can be lost in the 5 to 7 years after menopause, silently and painlessly. The good news: screening, strength training and treatments have proven themselves. You still need to know what to do, and when.
Bone at menopause: what is at stake, and when
Menopause-related bone loss is not steady: it accelerates sharply around the final menstrual period. The analysis of the SWAN cohort shows that the loss of bone mineral density is concentrated in a window surrounding the time of the final menstrual period (PMID 21976317). That is what makes this period strategic: it is the moment when action has the greatest effect, and it is also the time when nothing hurts. Osteoporosis is silent until the fracture.
Screening
Screening recommendations for bone densitometry (DXA) are well established and regularly updated, notably by the US Preventive Services Task Force (PMID 39808425) and in the clinical guide to the prevention and treatment of osteoporosis (PMID 35478046). The indication depends on age and risk factors: it is a medical decision, not a test to request systematically.
What has the most evidence: loading
The LIFTMOR trial tested, in postmenopausal women with low bone density, high-intensity resistance training combined with impact exercises, under supervision: the results on bone density and function were favorable, with good tolerance in a supervised setting (PMID 28975661). The message is not "lift heavy right away"; it is "bone responds to sufficient load, and walking alone is not enough". Progression must be supervised.
Preventing the fall as much as the fracture
It is often forgotten: a fracture is a fragile bone and a fall. A systematic review with meta-analysis shows that exercise reduces falls in older adults, with balance-focused programs being the most effective (PMID 27707740).
Treatments
Hormone therapy reduces fracture risk: in the estrogen plus progestin arm of the Women's Health Initiative, a reduction in fractures was demonstrated (PMID 14519707), and the Menopause Society's 2022 position statement sets out the framework for its use (PMID 35797481). For osteoporosis-specific treatments, the 2021 position statement is the reference (PMID 34448749). One important safety point: stopping denosumab exposes you to a rebound with a risk of vertebral fractures. This treatment is never interrupted without a bridging plan arranged by the physician (PMID 29105841).
This page is educational. No osteoporosis treatment should be started or stopped without medical advice.
Our articles on this topic
- Joint pain at menopause: what is true, what is falseMorning stiffness, painful knees, a blocked shoulder: what the studies really show about menopausal joint pain, and what works.
- Frozen shoulder: why it mostly strikes women aged 40 to 60Adhesive capsulitis: the sign that sets it apart from tendinitis, the real risk factors, what the menopause link is worth and what works.
- Osteoporosis after menopause: protecting your bonesUp to 20% of bone density lost in the 5-7 years after menopause. Understand why, get screened and act: calcium, vitamin D, strength training.
- Mouth and gums at menopause: what changesDry mouth, fragile gums, burning mouth: what the studies really show, and an honest framing of the risk of osteonecrosis of the jaw.
- Exercise after 50: what to change in your trainingAfter 50, cardio is no longer enough. Discover why strength training becomes the priority for your muscles, bones and metabolism, data included.
- Vitamin D and female hormones: its real roleImmunity, mood, muscles: the real role of vitamin D at menopause. What the studies show, the recommended doses and the mistakes to avoid.
- MHT at menopause: real benefits and risksMHT and menopause: what science really shows about the benefit-risk balance, the window of opportunity, the heart, bone and the breast.